PharmaPoint: Meningococcal Vaccines Spain Drug Forecast and Market Analysis to 2022. Meningococcal disease is an acute infection caused by the gram-negative bacterium Neisseria meningitidis. Its rapid onset and severity of symptoms makes prompt and effective diagnosis and treatment nearly impossible. For these reasons the meningococcal disease space is dominated by vaccines. Currently, tetravalent conjugate vaccines, such as Sanofis Menactra and Novartis Menveo, account for the vast majority of global sales, with the US adolescent market being the key target segment. GlobalData expects growth in the meningococcal vaccines market to be primarily driven by the launch of serotype B vaccines, which address a critical unmet need in the treatment landscape. Vaccines that better protect infants and/or provide a longer duration of immunity also have an opportunity to seize market share during 2012-2022.

1. PharmaPoint: Meningococcal Vaccines - Spain Drug Forecast and Market Analysis to 2022
GlobalData has released its new Country report, PharmaPoint: Meningococcal Vaccines Spain Drug Forecast
and Market Analysis to 2022. Meningococcal disease is an acute infection caused by the gram-negative
bacterium Neisseria meningitidis. Its rapid onset and severity of symptoms makes prompt and effective
diagnosis and treatment nearly impossible. For these reasons the meningococcal disease space is dominated by
vaccines. Currently, tetravalent conjugate vaccines, such as Sanofis Menactra and Novartis Menveo, account
for the vast majority of global sales, with the US adolescent market being the key target segment. GlobalData
expects growth in the meningococcal vaccines market to be primarily driven by the launch of serotype B
vaccines, which address a critical unmet need in the treatment landscape. Vaccines that better protect infants
and/or provide a longer duration of immunity also have an opportunity to seize market share during
2012-2022.
GlobalData predicts that relative patient share for the three MenC conjugate vaccines will remain unchanged
for the duration of the forecast period because Nuron Biotechs Meningitec, Novartis Menjugate kit, and
Baxters NeisVac-C possess nearly identical clinical profiles and price points. The MenC conjugate patient
share is largely determined by prescriber preference in Spain and therefore is not expected to change
drastically during the forecast period. In addition, GlobalData believes that an expected change in the booster
administration age, from two to 11 years of age, will not dramatically alter sales, although a small coverage
rate decrease associated with the older age group may occur (MSSSI, 2013).
Scope
Overview of Meningococcal Vaccines including epidemiology, etiology, symptoms, diagnosis, pathology
and treatment guidelines as well as an overview on the competitive landscape. Detailed information on the key
drugs in Spain including product description, safety and efficacy profiles as well as a SWOT analysis. Sales
forecast for the top drugs in Spain from 2012-2022. Analysis of the impact of key events as well the drivers
and restraints affecting Spain Meningococcal Vaccines market.
Reasons to buy
Understand and capitalize by identifying products that are most likely to ensure a robust return Stay ahead of
the competition by understanding the changing competitive landscape for Meningococcal Vaccines Effectively
plan your M&A and partnership strategies by identifying drugs with the most promising sales potential Make
more informed business decisions from insightful and in-depth analysis of drug performance Obtain sales
forecast for drugs from 2012-2022 in Spain
table Of Contents
1 Table Of Contents 1
1.1 List Of Tables 3
1.2 List Of Figures 3
PharmaPoint: Meningococcal Vaccines - Spain Drug Forecast and Market Analysis to 2022

2. 2 Executive Summary 4
2.1 Sales For Meningococcal Vaccine In Spain 4
3 Introduction 7
3.1 Catalyst 7
3.2 Related Reports 8
3.3 Upcoming Related Reports 10
4 Disease Overview 10
4.1 Etiology And Pathophysiology 11
4.1.1 Etiology 11
4.1.2 Pathophysiology 12
4.2 Symptoms 13
4.3 Prognosis 14
5 Disease Management 14
5.1 Meningococcal Immunization Policy 15
5.2 Spain 17
5.2.1 Meningococcal Immunization Recommendations And Policies 17
5.2.2 Clinical Practice 17
6 Competitive Assessment 19
6.1 Overview 19
6.2 Strategic Competitor Assessment 19
6.3 Product Profiles Major Brands 20
6.3.1 Menveo 20
6.3.2 Nimenrix 23
6.3.3 Meningitec 25
6.3.4 Menjugate 28
6.3.5 Neisvac-c 31
6.3.6 Bexsero 34
7 Opportunity And Unmet Need 36
7.1 Overview 36
7.2 Unmet Needs 37
7.2.1 Unmet Need: Protection Against Serogroup B Disease 37
7.2.2 Unmet Need: A Pentavalent (menabcwy) Vaccine 37
7.2.3 Unmet Need: More Cost-effective Vaccines 39
PharmaPoint: Meningococcal Vaccines - Spain Drug Forecast and Market Analysis to 2022

3. 7.2.4 Unmet Need: Improved Duration Of Immunity In Children And Adolescents 39
7.2.5 Unmet Need: Immunogenic Infant Vaccines 41
7.2.6 Unmet Need: Improved Vaccination Coverage Rates 42
7.2.7 Unmet Need: Increased Patient Awareness And Education 43
7.3 Unmet Needs Gap Analysis 44
7.4 Opportunities 45
7.4.1 Opportunity: Broadening Serogroup Protection With New And Existing Antigen Combinations 45
7.4.2 Opportunity: Improving Immune Response Duration With Adjuvants 46
7.4.3 Opportunity: Developing More Cost-effective Vaccines By Partnering With Manufacturers In Emerging
Markets 47
8 Pipeline Assessment 47
8.1 Overview 47
8.2 Promising Vaccines In Clinical Development 47
8.2.1 Mnb Rlp2086 51
8.3 Promising Vaccines In Early Clinical Development 56
8.3.1 Meninge Acyw Conj. 56
8.3.2 Menabcwy 60
8.3.3 Menc Conjugate 63
8.3.4 Heptavalent Dtp-hib-hepb-ipv-menc 66
9 Market Outlook 68
9.1 Spain 68
9.1.1 Forecast 68
9.1.2 Key Events 71
9.1.3 Drivers And Barriers 72
10 Appendix 74
10.1 Bibliography 74
10.2 Abbreviations 84
10.3 Methodology 86
10.4 Forecasting Methodology 86
10.4.1 Vaccine Coverage 87
10.4.2 Vaccine Approval Vs. Routine Schedule Inclusion 87
10.4.3 Vaccines Included 88
10.4.4 Key Launch Dates 89
10.4.5 General Pricing Assumptions 90
10.4.6 Individual Vaccine Assumptions 91
10.4.7 Pricing Of Pipeline Agents 96
10.5 Physicians And Specialists Included In This Study 97
PharmaPoint: Meningococcal Vaccines - Spain Drug Forecast and Market Analysis to 2022

4. 10.6 About The Authors 100
10.6.1 Authors 100
10.6.2 Reviewers 100
10.6.3 Global Head Of Healthcare 100
10.7 About Globaldata 101
10.8 Contact Us 101
10.9 Disclaimer 101
ResearchMoz(http://www.researchmoz.us/) is the one stop online destination to find and buy market research
reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our
huge collection of market research reports. We provide our services to all sizes of organizations and across all
industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as
publishers and will assist you in making an informed decision by giving you unbiased and deep insights on
which reports will satisfy your needs at the best price.
Contact:
M/s Sheela,
90 State Street,
Suite 700,
Albany NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-997-4948
Email: sales@researchmoz.us
Website: http://www.researchmoz.us/
PharmaPoint: Meningococcal Vaccines - Spain Drug Forecast and Market Analysis to 2022